Suppr超能文献

单克隆抗体AUA1及其F(ab')2片段在人肿瘤异种移植中的定位:放射自显影和免疫组织化学研究

Localization of monoclonal antibody AUA1 and its F(ab')2 fragments in human tumour xenografts: an autoradiographic and immunohistochemical study.

作者信息

Pervez S, Epenetos A A, Mooi W J, Evans D J, Rowlinson G, Dhokia B, Krausz T

机构信息

Department of Histopathology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.

出版信息

Int J Cancer Suppl. 1988;3:23-9. doi: 10.1002/ijc.2910410806.

Abstract

The mouse monoclonal antibody (MAb) AUA1, when applied on LoVo tumour sections, reacts by staining all tumour cells, on their cell surfaces. To investigate the accessibility of these sites to antibody when the tumour is present as a solid mass in vivo, subcutaneous xenografts of LoVo were first prepared in nude mice. The mice were then injected intravenously with either 125I-labelled AUA1, 125I AUA1 F(ab')2 or with 125I-labelled HMFG2 (negative control antibody). Animals were killed at various time intervals. Gross and micro-autoradiography as well as immunohistochemistry were performed on tissue samples of tumour and control organs. The in vivo injected antibody, in contrast to that studied in vitro, was localized only, as detected by autoradiography, on a thin layer of tumour cells adjacent to the vascularized stroma. On microscopically small tumour islands the antibody penetration was complete. Most of the radioactivity was on the cell surfaces, as seen on in vitro immunostaining. With intact antibody, similar autoradiographic results were obtained at days 1, 3 and 6. With F(ab')2 fragments there was deeper penetration into the tumour at days 1 and 3, though less radioactivity was found; by day 6 the activity had greatly decreased. Radioactivity in the control organs was limited to the blood pool. Negative control antibody HMFG2 showed no localization on the tumour cells. These results were not due to differences in antigenic expression of the tumour cells but reflect the problem of accessibility of antigenic sites in vivo.

摘要

小鼠单克隆抗体(MAb)AUA1应用于LoVo肿瘤切片时,可对所有肿瘤细胞的细胞表面进行染色。为了研究当肿瘤以实体瘤形式存在于体内时这些位点对抗体的可及性,首先在裸鼠体内制备LoVo皮下异种移植物。然后给小鼠静脉注射125I标记的AUA1、125I AUA1 F(ab')2或125I标记的HMFG2(阴性对照抗体)。在不同时间间隔处死动物。对肿瘤和对照器官的组织样本进行大体和显微放射自显影以及免疫组织化学分析。与体外研究的抗体不同,体内注射的抗体通过放射自显影检测仅定位在与血管化基质相邻的薄层肿瘤细胞上。在显微镜下的小肿瘤岛中,抗体穿透是完全的。如体外免疫染色所见,大部分放射性位于细胞表面。使用完整抗体时,在第1、3和6天获得了相似的放射自显影结果。使用F(ab')2片段时,在第1天和第3天肿瘤内的穿透更深,尽管发现的放射性较少;到第6天,活性已大大降低。对照器官中的放射性仅限于血池。阴性对照抗体HMFG2在肿瘤细胞上未显示定位。这些结果不是由于肿瘤细胞抗原表达的差异,而是反映了体内抗原位点的可及性问题。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验